tiprankstipranks
Trending News
More News >

Solvonis Therapeutics Secures Key U.S. Patent for AI-Driven CNS Compounds

Story Highlights
Solvonis Therapeutics Secures Key U.S. Patent for AI-Driven CNS Compounds

Don’t Miss TipRanks’ Half-Year Sale

Graft Polymer (UK) PLC ( (GB:SVNS) ) has issued an update.

Solvonis Therapeutics plc announced the allowance of a U.S. patent application for compounds within its AI-enabled CNS discovery program, marking a significant milestone for the company. The patent, expected to be granted soon, will provide U.S. exclusivity through 2043, bolstering Solvonis’ strategic positioning in the neuropsychiatry field by protecting its novel CNS-active compounds. This development enhances the company’s AI-supported drug discovery platform, which focuses on depression, stimulant use disorder, and other neuropsychiatric conditions, and validates the early-stage innovation acquired from Awakn Life Sciences Corp.

More about Graft Polymer (UK) PLC

Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Based in London and listed on the London Stock Exchange, Solvonis targets high-burden neuropsychiatric conditions with significant unmet needs, such as Alcohol Use Disorder and Post-Traumatic Stress Disorder. The company is advancing a differentiated pipeline of repurposed and novel compounds, with a capital-efficient model and dual development strategy.

Average Trading Volume: 44,036,262

Technical Sentiment Signal: Hold

Current Market Cap: £10.25M

For an in-depth examination of SVNS stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1